Fidelity bought 20,20,423 shares of Onesource Specialty Pharma Limited, a 1.76% stake, worth ₹334.02 Cr at ₹1653.20 apiece.
A specialist pharmaceutical company engaged in the research, development, and manufacturing of biological drug products in injectable formats for therapeutic use. OneSource Specialty Pharma provides comprehensive contract development and manufacturing organization services spanning all phases of preclinical and clinical development, alongside commercial supply of biologics to domestic and international pharmaceutical clients and healthcare providers.
Boston-based global active asset manager with India exposure through emerging market and India-focused funds.